Select a Region North America

洞察

Insights From Our Experts

Articles

The AI Revolution in HEOR: How ChatGPT-4o and Multi-AI Agents Are Shaping

Discover the future of Health Economics and Outcomes Research (HEOR) in our article, ‘The AI Revolution in HEOR’. Learn how AI, particularly ChatGPT-4o, is transforming the field with its enhanced speed and capabilities. Explore the potential…

A Review of Worldwide Indirect Treatment Comparison (ITC) Guidelines and Best Practices

Considering the challenges of conducting head-to-head clinical trials, indirect treatment comparisons (ITCs) offer valuable insights into clinical effectiveness that reflect current and local practices. These insights can help regulators and reimbursement agencies make better-informed decisions, thereby…

Navigating the PBAC: Strategies for Successful Reimbursement Applications

Authors: Ravi Visweswara, Executive Vice President, EVERSANA APAC; Robin Arnold, Executive Vice President, EVERSANA APAC; Amish Chaturvedi, Senior Director, Pricing and Market Access, EVERSANA APAC; Paul Lindsay, Senior Director, Pricing and Market Access, EVERSANA Australia Crafting…

Championing Women’s Health and Equity

At Radical Health Festival Helsinki, Sr Innovation Manager, Anastasiya Markvarde, moderated a women-led panel on Closing the Funding Gaps. In this piece, we’re sharing Anastasiya’s takeaways from the session, steering the conversation toward twocritical gaps: the…

FDA Guidance and Considerations for Scientific Exchange Communication Strategies

In light of draft guidance issued by the U.S. Food and Drug Administration (FDA) regarding the communication of scientific information of unapproved uses (SIUU) of approved medical medical products, EVERSANA continues to assess the potential risk…

Updated Guidance May Ease MDR Transition for SaMD Manufacturers

The regulation of medical devices in the EU has been chaotic since the implementation of Regulation (EU) 2017/745, known as the Medical Device Regulation (MDR). This upheaval has been particularly challenging for manufacturers facing a backlog…

Navigating the Evolution of Precision Medicine: Data-Driven Strategies for Life Sciences Commercialization

The landscape of pharmaceutical commercialization has undergone a remarkable transformation over the past decade. Traditional blockbuster drugs, once the hallmark of the industry, have given way to other products such as targeted therapeutics designed for rare…

M&A and BD&L Outlook and Perspectives on Commercial Due Diligence

In this webinar, industry leaders Faruk Abdullah, James Stephanou, Jakub Pijewski, PhD, and Yao Zhang, PhD, delve into the dynamic world of M&A, BD&L, and Commercial Due Diligence (CDD) in the pharmaceutical and biotech sectors. Gain…

Optimizing Patient-Centered Care: Strategies for Improving Health Outcomes

With a rapidly evolving health insurance landscape in India, it is imperative to understand the challenges and potential solutions for innovative medical technologies reimbursement by private health insurance in India. EVERSANA recently partnered with St. Jude…

Real-World Effectiveness of Treatments Post-CDK4/6i in Treating HR+/HER2- Locally Advanced or Metastatic Breast Cancer

Since the FDA’s approval of palbociclib plus letrozole in 2015, cyclin-dependent kinase 4/6 inhibitors (CDK4/6i), in combination with endocrine therapy (ET), have become the standard of care for treating hormone receptor-positive, human epidermal growth factor receptor…